Parathyroid hormone-related protein (107-139) increases human osteoblastic cell survival by activation of vascular endothelial growth factor receptor-2

Journal of Cellular Physiology

Volumn 217, Issue 3, 2008, Pages 717-727

  Alonso, Verónica ^a   De Gortázar, Arancha R ^a   Ardura, Juan A ^a   Andrade Zapata, Irene ^a   Alvarez Arroyo, M Victoria ^a   Esbrit, Pedro ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; ETOPOSIDE; METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PARATHYROID HORMONE RELATED PROTEIN; PARATHYROID HORMONE RELATED PROTEIN[107-139]; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; SU 1498; SU 5614; UNCLASSIFIED DRUG; VASCULOTROPIN 165; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 2 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PARATHYROID HORMONE RELATED PEPTIDE (1 36); PARATHYROID HORMONE RELATED PROTEIN (107 139); PARATHYROID HORMONE-RELATED PEPTIDE (1-36); PARATHYROID HORMONE-RELATED PROTEIN (107-139); PEPTIDE FRAGMENT; PHOSPHOTYROSINE; RUNX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR RUNX2; VASCULOTROPIN A;

AMINO TERMINAL SEQUENCE; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; CELL LINE; CYTOLOGY; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; METABOLISM; PHOSPHORYLATION;

CELL DEATH; CELL LINE; CELL SURVIVAL; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DEXAMETHASONE; ENZYME ACTIVATION; ETOPOSIDE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; OSTEOBLASTS; PARATHYROID HORMONE-RELATED PROTEIN; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PHOSPHOTYROSINE; PROTO-ONCOGENE PROTEINS C-AKT; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 54049099247     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21547     Document Type: Article

References (43)

1. Ahmed I, Gesty-Palmer D, Drezner MK, Luttrell LM. 2003. Transactivation of the epidermal growth factor receptor mediates parathyroid hormone and prostaglandin F2 alpha-stimulated mitogen-activated protein kinase activation in cultured transgenic murine osteoblasts. Mol Endocrinol 17:1607-1621.
2. Amling M, Neff L, Tanaka S, Inoue D, Kuida K, Weir E, Philbrick WM, Broadus AE, Baron R. 1997. Bcl-2 lies downstream of parathyroid hormone-related peptide in a signaling pathway that regulates chondrocyte maturation during skeletal development. J Cell Biol 136:205-213.
3. Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, Roberson PK, Weinstein RS, O'Brien CA, Manolagas SC, Jilka RL. 2003. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. J Biol Chem 278:50259-50272.
4. Bisello A, Horwitz MJ, Stewart AF. 2004. Parathyroid hormone-related protein: An essential physiological regulator of adult bone mass. Endocrinology 145:3551-3553.
5. Blyth K, Vaillant F, Hanlon L, Mackay N, Bell M, Jenkins A, Neil JC, Cameron ER. 2006. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo. Cancer Res 66:2195-2201.
6. Bu R, Borysenko CW, Li Y, Cao L, Sabokbar A, Blair HC. 2003. Expression, function of TNF-family, proteins, receptors in human osteoblasts. Bone 33:760-770.
7. Chen H-L, Demiralp B, Schneider A, Koh AJ, Silve C, Wang C-Y, McCauley LK. 2002. Parathyroid hormone and parathyroid hormone-related protein exert both pro- and anti-apoptotic effects in mesenchymal cells. J Biol Chem 277:19374-19381.
8. Cornish J, Callon KE, Nicholson GC, Reid IR. 1997. Parathyroid hormone-related protein (107-139) inhibits bone resorption in vivo. Endocrinology 138:1299-1304.
9. de Gortázar AR, Alonso V, Alvarez-Arroyo MV, Esbrit P. 2006. Transient exposure to PTHrP (107-139) exerts anabolic effects through vascular endothelial growth factor receptor 2 in human osteoblastic cells in vitro. Calcified Tissue Int 79:360-369.
10. Deckers MM, Karperien M, van der Bent C, Yamashita T, Papapoulos SE, Löwik CW. 2000. Expression of vascular endothelial growth factor and their receptors during osteoblast differentiation. Endocrinology 141:1667-1674.
11. Ducy P, Starbuck M, Priemel M, Shen J, Pinero G, Geoffroy V, Amling M, Karsenty G. 1999. A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev 13:1025-1036.
12. Esbrit P, Alvarez-Arroyo MV, de Miguel F, Martïn O, Martïnez ME, Caramelo C. 2000. C-terminal parathyroid hormone-related protein increases vascular endothelial growth factor in human osteoblastic cells. J Am Soc Nephrol 11:1085-1092.
13. Esbrit P, Benïtez-Verguizas J, de Miguel F, Valïn A, Garcïa-Ocaña A. 2000. Characterization of parathyroid hormone/parathyroid hormone-related protein receptor and signaling in hypercalcemic Walker 256 tumor cells. J Endocrinol 166:11-20.
14. Franceschi RT, Xiao G, Jiang D, Gopalakrishnan R, Yang S, Reith E. 2003. Multiple signaling pathways converge on the Cbfa1/Runx2 transcription factor to regulate osteoblast differentiation. Connect Tissue Res 44:109-116.
15. Fujita Y, Yoshizumi M, Izawa Y, Ali N, Ohnishi H, Kanematsu Y, Ishizawa K, Tsuchiya K, Tamaki T. 2006. Transactivation of fetal liver kinase-1/kinase-insert domain-containing receptor by lysophosphatidylcholine induces vascular endothelial cell proliferation. Endocrinology 147:1377-1385.
16. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N. 1998. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 30-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273:30336-30343.
17. Guillén C, Martínez P, de Gortázar AR, Martínez ME, Esbrit P. 2002. Both N- and C-terminal domains of parathyroid hormone-related protein increase interleukin-6 y NF-kB activation in osteoblastic cells. J Biol Chem 277:28109-28117.
18. Hastings RH, Araiza F, Burton DW, Bedley M, Deftos LJ. 2004. Parathyroid hormone-related protein regulates apoptosis in lung cancer cells through protein kinase A. Am J Physiol Cell Physiol 287:C1616-C1622.
19. Hock JM, Krishnan V, Onyia JE, Bidwell JP, Milas J, Stanislaus D. 2001. Osteoblast apoptosis and bone turnover. J Bone Miner Res 16:975-984.
20. Inman CK, Shore P. 2003. The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J Biol Chem 278:48684-48689.
21. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. 1999. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104:439-446.
22. Jilka RL, Weinstein RS, Parfitt AM, Manolagas SC. 2007. Quantifying osteoblast and osteocyte apoptosis: Challenges and rewards. J Bone Miner Res 22:1492-1501.
23. Maes C, Carmeliet P, Moermans K, Stockmans I, Smets N, Collen D, Bouillon R, Carmeliet G. 2002. Impaired angiogenesis and endochondral bone formation inmice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech Dev 111:61-73.
24. Mathews TM, Berk BC. 2008. PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2. Arterioscler Thromb Vasc Biol 28:711-717.
25. Miao D, He B, Jiang Y, Kobayashi T, Soroceanu MA, Zhao J, Tong X, Amizuka N, Gupta A, Genant HK, Kronenber HM, Goltzman D, Karaplis AC. 2005. Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH1-34. J Clin Invest 115:2402-2411.
26. Miao D, Su H, He B, Gao J, Xia Q, Goltzman D, Karaplis AC. 2005. Deletion of the mid- and carboxyl regions of PTHrP produces growth retardation and early senescence in mice. J Bone Miner Res 20:S14.
27. Miyaji T, Nakase T, Onuma E, Sato K, Myoui A, Tomita T, Jovama S, Ariga K, Hashimoto J, Ueda T, Yoshikawa H. 2003. Monoclonal antibody to parathyroid hormone-related protein induces differentiation and apoptosis of chondrosarcoma cells. Cancer Lett 199:147-155.
28. Ortega A, Rámila D, Ardura JA, Esteban V, Ruiz-Ortega M, Barat A, Gazapo R, Bosch RJ, Esbrit P. 2006. Role of parathyroid hormone-related protein in tubulointerstitial apoptosis and fibrosis after folic acid-induced nephrotoxicity. J Am Soc Nephrol 17:1594-1603.
29. Pantschenko AG, Zhang W, Nahounou M, McCarthy MB, Stover ML, Lichtler AC, Clark SH, Gronowicz GA. 2005. Effect of osteoblast-targeted expression of bcl-2 in bone: Differential response in male and female mice. J Bone Miner Res 20:1414-1429.
30. Peng H, Usas A, Olshanski A, Ho AM, Gearhart B, Cooper GM, Huard J. 2005. VEGF improves, whereas sFlt1 inhibts, BMP2-induced bone formation and bone healing through modulation of angiogenesis. J Bone Miner Res 20:2017-2027.
31. Petreaca ML, Yao M, Liu Y, DeFea K, Martins-Green M. 2007. Transactivation of vascular endothelial growth factor receptor-2 (VEGFR2) by interleukin-8 (IL-8/CXCL8) is required for IL-8/CXCL8-induced endothelial permeability. Mol Biol Cell 18:5014-5023.
32. Raisz LG. 2005. Pathogenesis of osteoporosis: Concepts, conflicts, and prospects. J Clin Invest 115:3318-3325.
33. Santos SC, Dias S. 2004. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood 103:3883-3889.
34. Tanimoto T, Jin ZG, Berk BC. 2002. Transactivation of vascular endothelial growth factor (VEGF) receptor Flk-1/KDR is involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt and endothelial nitric-oxide synthase (eNOS). J Biol Chem 277:42997-43001.
35. Tashjian AH, Gagel RF. 2006. Teriparatide [human PTH (1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 21:354-365.
36. Tomkinson A, Reeve J, Shaw RW, Noble BS. 1997. The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J Clin Endocrinol Metab 82:3128-3135.
37. Towler DA. 2007. Vascular biology and bone formation: Hints from HIF. J Clin Invest 117:1477-1480.
38. Valín A, Guillén C, Esbrit P. 2001. C-terminal parathyroid hormone-related protein (PTHrP) (107-139) stimulates intracellular Ca2+ through a receptor different from the type 1 PTH/PTHrP receptor in osteoblastic osteosarcoma UMR 106 cells. Endocrinology 142:2752-2759.
39. Villegas G, Lange-Sperandio B, Tufro A. 2005. Autocrine and paracrine functions of vascular endothelial growth factor (VEGF) in renal tubular epithelial cells. Kidney Int 67:449-457.
40. Weinstein R, Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. 1998. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102:274-282.
41. Whitfield JF. 2007. Parathyroid hormone-related protein (PTHrP): An ancient string of cytokines with many known and still unknown functions. In: Luparello C, editor. Novel aspects of PTHrP physiopathology. New York: Nova Science Publishers, Inc. pp 1-25.
42. Zhang R, Xu Y, Ekman N, Wu Z, Wu J, Alitalo K, Min W. 2003. Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway. J Biol Chem 278:51267-51276.
43. Zilberberg L, Shinkaruk S, Lequin O, Rousseau B, Hagedorn M, Costa F, Caronzolo D, Balke M, Canron X, Convert O, Lain G, Gionnet K, Gonçalves M, Bayle M, Bello L, Chassaing G, Deleris G, Bikfalvi A. 2003. Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor. J Biol Chem 278:35564-35573.